Detalhe da pesquisa
1.
PLCG1 is required for AML1-ETO leukemia stem cell self-renewal.
Blood
; 139(7): 1080-1097, 2022 02 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-34695195
2.
Immunoproteasome function maintains oncogenic gene expression in KMT2A-complex driven leukemia.
Mol Cancer
; 22(1): 196, 2023 12 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38049829
3.
Cre recombinase expression cooperates with homozygous FLT3 internal tandem duplication knockin mouse model to induce acute myeloid leukemia.
Leukemia
; 37(4): 741-750, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36739348
4.
Cell fate determinant Llgl1 is required for propagation of acute myeloid leukemia.
Leukemia
; 37(10): 2027-2035, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37587260
5.
Context-specific effects of NOX4 inactivation in acute myeloid leukemia (AML).
J Cancer Res Clin Oncol
; 148(8): 1983-1990, 2022 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-35348887
6.
Combined Activity of the Redox-Modulating Compound Setanaxib (GKT137831) with Cytotoxic Agents in the Killing of Acute Myeloid Leukemia Cells.
Antioxidants (Basel)
; 11(3)2022 Mar 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35326163
7.
YBX1 mediates translation of oncogenic transcripts to control cell competition in AML.
Leukemia
; 36(2): 426-437, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34465866
8.
A JAK of all trades: how global phosphoproteomics reveal the Achilles heel of MPNs.
Mol Cell Oncol
; 8(2): 1871172, 2021 Jan 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-33855167
9.
The cell fate determinant Scribble is required for maintenance of hematopoietic stem cell function.
Leukemia
; 32(5): 1211-1221, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29467485
10.
JAK2-V617F promotes venous thrombosis through ß1/ß2 integrin activation.
J Clin Invest
; 128(10): 4359-4371, 2018 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30024857
11.
SHP1 regulates a STAT6-ITGB3 axis in FLT3ITD-positive AML cells.
Leukemia
; 34(5): 1444-1449, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31836852
12.
Rapid induction of complete molecular remission by sequential therapy with LDAC and sorafenib in FLT3-ITD-positive patients unfit for intensive treatment: two cases and review of the literature.
J Hematol Oncol
; 6: 39, 2013 Jun 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-23759001